查看購物車
  • Simplified Chinese
  • English
再生醫學市場規模及預測（2021-2031年），全球及區域佔有率、趨勢和成長機會分析報告涵蓋範圍：按產品類型、應用和地理分類
市場調查報告書
商品編碼
1858555

再生醫學市場規模及預測（2021-2031年），全球及區域佔有率、趨勢和成長機會分析報告涵蓋範圍：按產品類型、應用和地理分類

Regenerative Medicine Market Size and Forecast 2021-2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage:By Product Type, Application, and Geography
出版日期: | 出版商: The Insight Partners | 英文 231 Pages | 訂單完成後即時交付

價格

根據我們最新發布的題為《2031年全球再生醫學市場預測－按產品類型和應用分類的分析》的研究報告，再生醫學市場規模將從2024年的205.5億美元成長到2031年的751.6億美元，複合年成長率（CAGR）預計為20.3%。再生醫學市場的成長主要歸因於慢性疾病盛行率的上升、人口老化以及先進再生療法的引入。

再生醫學是生物醫學的一個分支，專注於修復、替換或再生受損或病變的細胞、組織或器官，以恢復其正常功能。它結合了幹細胞療法、組織工程、基因療法和生物材料等多種方法，以促進癒合和再生。

北美再生醫學市場分為美國、加拿大和墨西哥三個部分。美國佔最大的市場佔有率，其次是加拿大。根據美國疾病管制與預防中心（CDC）統計，美國每40秒就會發生一起心臟病發作，每年約有80.5萬人患有此病。癌症是導致發病率和死亡率的主要原因，不僅造成巨大的醫療成本，也嚴重影響病患的生活品質。慢性病和退化性疾病的日益普遍，使得人們對再生療法等新型治療方法的需求不斷成長。

再生醫學在北美常見疾病的治療方面具有變革性潛力，尤其是在心血管疾病、糖尿病和某些類型的癌症方面。幹細胞療法、基因編輯和組織工程的進展在這些領域展現出良好的前景。多種CAR-T細胞療法已獲得FDA批准，用於治療血液系統惡性腫瘤，例如多發性骨髓瘤和淋巴瘤。

慢性病和退化性疾病負擔日益加重，推動了再生醫學領域在研究、生物製造和人才培養方面的投資。這個生態系統促進了快速創新，並提高了治療方案的可及性和精細化程度。 2022年1月，總部位於美國的自主細胞療法生產公司Cellino Biotech, Inc.完成了由拜耳旗下Leaps by Bayer領投的8000萬美元A輪融資，8VC和洪堡基金也參與了此次融資。 Cellino的創新製造平台結合了人工智慧和雷射技術，實現了細胞療法生產的自動化，旨在降低成本並提高規模化生產能力。這項投資為Leaps by Bayer提供了一個獨特的機會，使其能夠支持先進療法的開發，從而提高患者獲得細胞治療的機會。

在北美，美國佔據再生醫學市場的重要佔有率。 2024年，美國在北美再生醫學市場佔據主導地位。根據美國疾病管制與預防中心（CDC）的數據顯示，2023年，76.4%的美國成年人（超過1.94億人）至少患有一種慢性病。其中超過一半（51.4%，即1.31億人）報告患有兩種或兩種以上慢性疾病。成年人中至少患有一種慢性疾病的比例從72.3%上升至76.4%。患有兩種或兩種以上慢性疾病的成年人比例從47.3%上升至51.4%。

根據阿茲海默症協會預測，到2025年，美國將有超過720萬65歲及以上的老年人患有阿茲海默症，到2050年，這一數字預計將成長至1270萬。心血管疾病、癌症和神經退化性疾病等慢性疾病會導致組織或器官的不可逆損傷，因此這些患者是幹細胞療法、組織工程和基因療法等再生療法的理想對象。再生醫學在以下方面展現出巨大潛力：心臟病發作後恢復心臟功能、再生退化性關節疾病中的軟骨以及替換神經退化性疾病中受損的神經元。在美國，間質幹細胞（MSCs）常用於治療退化性疾病以及某些皮膚、骨骼和軟骨疾病。

美國政府正透過監管創新、加速核准流程、直接資助和合作技術支持，推動再生療法的研發和批准。截至2025年中期，已有超過80項再生醫學先進療法（RMAT）獲得認定，有助於加速脊髓損傷和心臟衰竭等疾病的臨床進展。 2023年，美國FDA批准了包括針對罕見疾病的基因編輯療法在內的多種細胞和基因療法。例如，用於治療鐮狀細胞貧血症的exagamglogene autotemcel（Casgevy）和lovotibeglogene autotemcel，以及用於治療重度血友病A的valoctocogene roxaparvovec等療法均已獲得FDA批准，凸顯了基因療法在應對罕見疾病挑戰方面的巨大潛力。因此，慢性病發病率的不斷上升，以及為促進再生技術應用而持續進行的研究和核准舉措，正在推動美國再生醫學市場的成長。

將人工智慧應用於再生醫學，將在未來帶來市場機會

將人工智慧 (AI) 應用於再生醫學，能夠促進藥物發現，改善個人化療法，並加速研發進程。 AI 驅動的技術有助於處理複雜的生物資料並最佳化生產流程，從而提高再生療法的效率。 Aspen Neuroscience 的 ANPD-001 目前正處於帕金森氏症 II 期臨床試驗階段，它是一種開創性的 AI 賦能再生療法。該療法利用 AI 和機器學習 (ML) 將患者的皮膚細胞重編程為多巴胺能神經元。專有的基於 AI 的基因組檢測可確保細胞質量，從而實現更安全、更個性化的治療。這種方法展示了 AI 驗證如何提高再生醫學產品的精準性和生物安全性，同時降低排斥風險。

多家新創公司進一步印證了這個趨勢。阿根廷公司 MesencHyal-T 利用人工智慧驅動的細胞療法，致力於骨骼再生。該公司在其可擴展的生產流程中運用機器學習技術，以標準化幹細胞擴增並提高細胞的成骨潛能。此外，該公司還與醫院和研究中心合作，以加速臨床應用，展現了人工智慧如何幫助發現、實際應用以及結果預測。同樣，總部位於英國的 Trogenix 公司將基因組學、生物資訊學和機器學習技術整合到其合成超級增強子病毒免疫療法中，用於精準基因控制和靶向再生治療，以治療癌症和老化相關組織損傷。

人工智慧驅動的平台輔助產品上市，加速候選藥物的研發。人工智慧藥物發現領域的領導企業Insilico Medicine憑藉其用於治療特發性肺纖維化的小分子候選藥物INS018_055取得了里程碑式的進展。該藥物是第一個完全由人工智慧發現和設計的、進入II期臨床試驗的藥物。 Insilico與製藥巨頭賽諾菲達成了一項價值12億美元的合作協議，該協議利用Insilico的人工智慧平台來識別新的目標並預測臨床結果，凸顯了以人工智慧驅動的再生醫學解決方案為中心的合作生態系統。

在製造和治療設計方面，像總部位於美國的Shinobi Therapeutics這樣的公司利用人工智慧平台開發免疫逃脫誘導多能幹細胞（iPSC）療法，其特點是經過基因編輯，可以逃避免疫系統的檢測。這種策略提供了適用於腫瘤、糖尿病和自體免疫疾病的現成再生療法，展現了人工智慧如何簡化先進再生產品所需的複雜基因工程。

人工智慧有助於克服再生醫學領域的許多挑戰，例如高昂的研發成本和漫長的研發週期。它能夠提升預測建模、品質控制和生產規模化能力。人工智慧演算法分析大量資料集，預測患者對幹細胞療法的具體反應，從而幫助制定個人化治療方案並改善臨床療效。產業預測顯示，到2025年，人工智慧的應用將大幅成長，成為全球再生醫學個人化治療方案的基礎。

人工智慧在再生醫學領域的應用代表著一項突破性趨勢。人工智慧能夠簡化療法研發流程，並提升個人化、品質和臨床療效。這種方法將使再生醫學在未來幾年迎來前所未有的成長，並造福更多患者，凸顯了尖端技術與生物創新融合的趨勢，從而徹底革新再生療法的設計、測試和應用。

在編制再生醫學市場報告時，參考的主要和次要來源包括美國食品藥物管理局 (FDA)、藥品和保健產品監管局 (MHRA) 以及再生醫學聯盟 (ARM)。

目錄

第1章：引言

第2章：執行概要

  • 分析師市場展望
  • 市場吸引力

第3章：研究方法

  • 二手研究
  • 初步研究
    • 假設的提出：
    • 宏觀經濟因素分析：
    • 發展基礎數字：
    • 數據三角測量：
    • 國家層面資料：
  • 假設和局限性

第4章：再生醫學市場概況

  • 概述
  • PEST分析

第5章：再生醫學市場－主要市場動態

  • 再生醫學市場－主要市場動態
  • 市場促進因素
    • 慢性疾病盛行率上升和人口老化
    • 先進再生療法的介紹
  • 市場限制
    • 再生治療中的高成本障礙
  • 市場機遇
    • 對個人化和精準醫療的需求激增
  • 未來趨勢
    • 人工智慧在再生醫學的應用
  • 駕駛員和安全帶的影響：

第6章：再生醫學市場－全球市場分析

  • 2021-2031年再生醫學市場收入
  • 再生醫學市場預測分析

第7章：再生醫學市場分析－依產品類型分類

  • 細胞製品
  • 基因療法
  • 組織工程

第8章：再生醫學市場分析－按應用領域分類

  • 腫瘤學
  • 神經系統疾病
  • 傷口癒合和皮膚再生
  • 眼科
  • 骨科和肌肉骨骼
  • 免疫學
  • 遺傳性疾病
  • 其他

第9章：再生醫學市場—地理分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 亞太其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 中東和非洲其他地區
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地區

第10章：競爭格局

  • 關鍵參與者熱力圖分析
  • 公司定位與集中度

第11章：行業概況

  • 概述
  • 產品上市，產品核准
  • 擴張及其他策略發展

第12章：公司簡介

  • Bristol-Myers Squibb Co
  • Novartis AG
  • Johnson & Johnson
  • Daiichi Sankyo Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • Japan Tissue Engineering Co., Ltd.
  • Bluebird Bio Inc
  • JCR Pharmaceuticals Co. Ltd.
  • Vertex Pharmaceuticals Inc
  • Ferring Pharmaceuticals
  • CSL Behring LLC
  • BioMarin Pharmaceutical Inc.

第13章：附錄

Product Code: TIPRE00040655

According to our new research study on "Regenerative Medicine Market Forecast to 2031 -Global Analysis - by Product Type, and Application," the market is anticipated to grow from US$ 20.55 billion in 2024 to US$ 75.16 billion by 2031; the market is expected to register a CAGR of 20.3%. The regenerative medicine market growth is attributed to the rising prevalence of chronic disorders, an aging population, and the introduction of advanced regenerative therapies.

Regenerative medicine is a field of biomedical science focusing on repairing, replacing, or regenerating damaged or diseased cells, tissues, or organs to restore normal function. It combines approaches from stem cell therapy, tissue engineering, gene therapy, and biomaterials to promote healing and regeneration.

The regenerative medicine market in North America is segmented into the US, Canada, and Mexico. The US holds the largest market share, followed by Canada. According to the Centers for Disease Control and Prevention (CDC), a heart attack occurs every 40 seconds in the US, with approximately 805,000 people experiencing it each year. Cancer is a major cause of morbidity and mortality, with significant healthcare costs and quality-of-life implications. The rising prevalence of chronic and degenerative conditions is increasing the demand for novel treatment approaches such as regenerative therapies.

Regenerative medicine holds transformative potential for prevalent diseases in North America, particularly cardiovascular diseases, diabetes, and certain types of cancer. Advances in stem cell therapies, gene editing, and tissue engineering are showing promise in these areas. Several CAR-T cell therapies have received FDA approval for treating hematological malignancies, such as multiple myeloma and lymphoma.

The rising burden of chronic and degenerative diseases is driving investments in research, biomanufacturing, and workforce development within the regenerative medicine sector. This ecosystem fosters rapid innovation and enhances the availability and sophistication of treatment options. In January 2022, Cellino Biotech, Inc., a US-based autonomous cell therapy manufacturing company, completed an US$ 80 million Series A financing round led by Bayer AG's Leaps by Bayer, alongside 8VC and the Humboldt Fund. Cellino's innovative manufacturing platform combines artificial intelligence and laser technology to automate cell therapy production, aiming to lower costs and improve scalability. This investment offers Leaps by Bayer a unique opportunity to support the development of advanced therapies that enhance patient access to cell treatments.

In North America, the US holds a significant share of the regenerative medicine market. The US dominated the North America regenerative medicine market in 2024. According to the CDC, in 2023, 76.4% of US adults, over 194 million people, had at least one chronic condition. More than half of these individuals (51.4%, or 131 million) reported having two or more chronic conditions. The prevalence of at least one chronic condition among adults increased from 72.3% to 76.4%. The percentage of adults with two or more chronic conditions rose from 47.3% to 51.4%.

According to the Alzheimer's Association, by 2025, more than 7.2 million Americans aged 65 and older are projected to be living with Alzheimer's, with that number expected to grow to 12.7 million by 2050. Chronic illnesses such as cardiovascular diseases, cancer, and neurodegenerative disorders lead to irreversible damage to tissues or organs, making patients prime candidates for regenerative therapies such as stem cell therapy, tissue engineering, and gene therapy. Regenerative medicine shows promise in restoring lost heart function after heart attacks, regenerating cartilage in cases of degenerative joint diseases, and replacing damaged neurons in neurodegenerative disorders. In the US, MSCs are commonly used to treat degenerative diseases and certain diseases of the skin, bone, and cartilage.

The US government is promoting the development and approval of regenerative therapies by utilizing regulatory innovation, expedited approval processes, direct funding, and collaborative technical support. As of mid-2025, more than 80 Regenerative Medicine Advanced Therapy (RMAT) designations have been awarded, which have helped speed up clinical advancements for conditions such as spinal cord injuries and heart failure. In 2023, the US FDA approved cell and gene therapies, including gene-editing treatments targeting rare diseases. Therapies such as exagamglogene autotemcel (Casgevy) and lovotibeglogene autotemcel for sickle cell disease, as well as valoctocogene roxaparvovec for severe hemophilia A, have received FDA approval, highlighting the potential of gene therapies in addressing rare disease challenges. Thus, the increasing incidence of chronic diseases, coupled with ongoing research and approval initiatives to promote the adoption of regenerative technologies, is fueling the market growth in the US.

Integration of Artificial Intelligence in Regenerative Medicine to Provide Market Opportunities in Future

Integrating artificial intelligence (AI) into regenerative medicine enhances drug discovery, improves personalized therapies, and accelerates development timelines. AI-driven technologies facilitate handling complex biological data and optimizing manufacturing processes, leading to more efficient regenerative therapies. Aspen Neuroscience's ANPD-001, currently in Phase II clinical trials for Parkinson's disease, exemplifies a pioneering AI-enabled regenerative therapy. This therapy utilizes AI and machine learning (ML) to reprogram patient skin cells into dopamine-producing neurons. Proprietary AI-based genomic tests ensure cell quality, resulting in safer, more personalized treatments. This approach demonstrates how AI validation can enhance the precision and biological safety of regenerative medicine products while reducing the risk of rejection.

Several startups illustrate this trend further. The Argentinian company MesencHyal-T employs AI-powered cellular therapies aimed at bone regeneration. It uses machine learning in its scalable production processes to standardize stem cell expansion and improve the osteogenic potential of the cells. Additionally, it collaborates with hospitals and research centers to facilitate quicker clinical deployment, showing how AI aids in discovery as well as real-world applications and outcome predictions. Similarly, the UK-based company Trogenix integrates genomics, bioinformatics, and machine learning into its synthetic super-enhancer viral immunotherapy for precise gene control and targeted regenerative treatments in cancer and age-related tissue repair.

AI-driven platforms contribute to product launches that accelerate drug candidate generation. Insilico Medicine, a leader in AI drug discovery, achieved a milestone with INS018_055, a small-molecule drug candidate for idiopathic pulmonary fibrosis. This drug is the first entirely AI-discovered and AI-designed medication to enter Phase II trials. Insilico's collaboration with pharmaceutical giant Sanofi, a US$1.2 billion deal, leverages Insilico's AI platform to identify novel targets and predict clinical outcomes, highlighting the ecosystem of partnerships centered around AI-driven regenerative solutions.

In manufacturing and therapy design, companies such as US-based Shinobi Therapeutics utilize AI-enabled platforms to develop immune-evasive induced pluripotent stem cell (iPSC) therapies, featuring genetic edits that evade immune detection. This strategy offers off-the-shelf regenerative treatments suitable for oncology, diabetes, and autoimmune disorders, showcasing how AI simplifies the complex genetic engineering required for advanced regenerative products.

AI helps overcome challenges in regenerative medicine, such as high developmental costs and lengthy timelines. It enhances predictive modeling, quality control, and scaling up production. AI algorithms analyze vast datasets to predict patient-specific responses to stem cell therapies, aiding in creating personalized treatment plans and improving clinical outcomes. Industry forecasts for 2025 suggest that AI adoption will increase dramatically, becoming foundational in personalizing regenerative protocols worldwide.

The integration of AI in regenerative medicine represents a groundbreaking trend. AI streamlines therapy development and enhances personalization, quality, and clinical effectiveness. This approach positions regenerative medicine for unprecedented growth and patient impact in the coming years, underscoring the convergence of cutting-edge technology with biological innovation to revolutionize the design, testing, and delivery of regenerative therapies.

The US Food and Drug Administration, Medicines and Healthcare Products Regulatory Agency (MHRA), Alliance for Regenerative Medicine (ARM) are among the primary and secondary sources referred to while preparing the regenerative medicine market report.

Table Of Contents

1. Introduction

  • 1.1 Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Analyst Market Outlook
  • 2.2 Market Attractiveness

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:
  • 3.3 Assumptions and Limitations

4. Regenerative Medicines Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis

5. Regenerative Medicines Market - Key Market Dynamics

  • 5.1 Regenerative Medicines Market - Key Market Dynamics
  • 5.2 Market Drivers
    • 5.2.1 Rising Prevalence of Chronic Disorders and Aging Population
    • 5.2.2 Introduction of Advanced Regenerative Therapies
  • 5.3 Market Restraints
    • 5.3.1 High-Cost Barriers in Regeneration Treatment
  • 5.4 Market Opportunities
    • 5.4.1 Surging Demand for Personalized and Precision Medicine
  • 5.5 Future Trends
    • 5.5.1 Integration of Artificial Intelligence in Regenerative Medicine
  • 5.6 Impact of Drivers and Restraints:

6. Regenerative Medicines Market - Global Market Analysis

  • 6.1 Regenerative Medicines Market Revenue (US$ Million), 2021-2031
  • 6.2 Regenerative Medicines Market Forecast Analysis

7. Regenerative Medicines Market Analysis - by Product Type

  • 7.1 Cell Based Products
    • 7.1.1 Overview
    • 7.1.2 Cell Based Products: Regenerative Medicines Market - Revenue and Forecast to 2031 (US$ Million)
        • 7.1.2.1.1 Global: Regenerative Medicines Market Breakdown, by Cell Based Products
  • 7.2 Gene Therapy
    • 7.2.1 Overview
    • 7.2.2 Gene Therapy: Regenerative Medicines Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.3 Tissue Engineering
    • 7.3.1 Overview
    • 7.3.2 Tissue Engineering: Regenerative Medicines Market - Revenue and Forecast to 2031 (US$ Million)

8. Regenerative Medicines Market Analysis - by Application

  • 8.1 Oncology
    • 8.1.1 Overview
    • 8.1.2 Oncology: Regenerative Medicines Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 Neurological Disorders
    • 8.2.1 Overview
    • 8.2.2 Neurological Disorders: Regenerative Medicines Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 Wound Healing and Skin Regeneration
    • 8.3.1 Overview
    • 8.3.2 Wound Healing and Skin Regeneration: Regenerative Medicines Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.4 Ophthalmology
    • 8.4.1 Overview
    • 8.4.2 Ophthalmology: Regenerative Medicines Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.5 Orthopedics and Musculoskeletal
    • 8.5.1 Overview
    • 8.5.2 Orthopedics and Musculoskeletal: Regenerative Medicines Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.6 Immunology
    • 8.6.1 Overview
    • 8.6.2 Immunology: Regenerative Medicines Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.7 Genetic Disorders
    • 8.7.1 Overview
    • 8.7.2 Genetic Disorders: Regenerative Medicines Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.8 Others
    • 8.8.1 Overview
    • 8.8.2 Others: Regenerative Medicines Market - Revenue and Forecast to 2031 (US$ Million)

9. Regenerative Medicines Market - Geographical Analysis

  • 9.1 North America
    • 9.1.1 North America Regenerative Medicines Market Overview
    • 9.1.2 North America: Regenerative Medicines Market - Revenue, 2021-2031 (US$ Million)
      • 9.1.2.1 North America: Regenerative Medicines Market - Revenue and Forecast Analysis - by Product Type
      • 9.1.2.2 North America: Regenerative Medicines Market - Revenue and Forecast Analysis - by Cell Based Products
      • 9.1.2.3 North America: Regenerative Medicines Market - Revenue and Forecast Analysis - by Application
    • 9.1.3 North America: Regenerative Medicines Market - Revenue and Forecast Analysis - by Country
      • 9.1.3.1 United States: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.1.3.1.1 United States: Regenerative Medicines Market Breakdown, by Product Type
        • 9.1.3.1.2 United States: Regenerative Medicines Market Breakdown, by Cell Based Products
        • 9.1.3.1.3 United States: Regenerative Medicines Market Breakdown, by Application
      • 9.1.3.2 Canada: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.1.3.2.1 Canada: Regenerative Medicines Market Breakdown, by Product Type
        • 9.1.3.2.2 Canada: Regenerative Medicines Market Breakdown, by Cell Based Products
        • 9.1.3.2.3 Canada: Regenerative Medicines Market Breakdown, by Application
      • 9.1.3.3 Mexico: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.1.3.3.1 Mexico: Regenerative Medicines Market Breakdown, by Product Type
        • 9.1.3.3.2 Mexico: Regenerative Medicines Market Breakdown, by Cell Based Products
        • 9.1.3.3.3 Mexico: Regenerative Medicines Market Breakdown, by Application
  • 9.2 Europe
    • 9.2.1 Europe Regenerative Medicines Market Overview
    • 9.2.2 Europe: Regenerative Medicines Market - Revenue, 2021-2031 (US$ Million)
      • 9.2.2.1 Europe: Regenerative Medicines Market - Revenue and Forecast Analysis - by Product Type
      • 9.2.2.2 Europe: Regenerative Medicines Market - Revenue and Forecast Analysis - by Cell Based Products
      • 9.2.2.3 Europe: Regenerative Medicines Market - Revenue and Forecast Analysis - by Application
    • 9.2.3 Europe: Regenerative Medicines Market - Revenue and Forecast Analysis - by Country
      • 9.2.3.1 Germany: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.2.3.1.1 Germany: Regenerative Medicines Market Breakdown, by Product Type
        • 9.2.3.1.2 Germany: Regenerative Medicines Market Breakdown, by Cell Based Products
        • 9.2.3.1.3 Germany: Regenerative Medicines Market Breakdown, by Application
      • 9.2.3.2 United Kingdom: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.2.3.2.1 United Kingdom: Regenerative Medicines Market Breakdown, by Product Type
        • 9.2.3.2.2 United Kingdom: Regenerative Medicines Market Breakdown, by Cell Based Products
        • 9.2.3.2.3 United Kingdom: Regenerative Medicines Market Breakdown, by Application
      • 9.2.3.3 France: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.2.3.3.1 France: Regenerative Medicines Market Breakdown, by Product Type
        • 9.2.3.3.2 France: Regenerative Medicines Market Breakdown, by Cell Based Products
        • 9.2.3.3.3 France: Regenerative Medicines Market Breakdown, by Application
      • 9.2.3.4 Italy: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.2.3.4.1 Italy: Regenerative Medicines Market Breakdown, by Product Type
        • 9.2.3.4.2 Italy: Regenerative Medicines Market Breakdown, by Cell Based Products
        • 9.2.3.4.3 Italy: Regenerative Medicines Market Breakdown, by Application
      • 9.2.3.5 Spain: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.2.3.5.1 Spain: Regenerative Medicines Market Breakdown, by Product Type
        • 9.2.3.5.2 Spain: Regenerative Medicines Market Breakdown, by Cell Based Products
        • 9.2.3.5.3 Spain: Regenerative Medicines Market Breakdown, by Application
      • 9.2.3.6 Rest of Europe: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.2.3.6.1 Rest of Europe: Regenerative Medicines Market Breakdown, by Product Type
        • 9.2.3.6.2 Rest of Europe: Regenerative Medicines Market Breakdown, by Cell Based Products
        • 9.2.3.6.3 Rest of Europe: Regenerative Medicines Market Breakdown, by Application
  • 9.3 Asia Pacific
    • 9.3.1 Asia Pacific Regenerative Medicines Market Overview
    • 9.3.2 Asia Pacific: Regenerative Medicines Market - Revenue, 2021-2031 (US$ Million)
      • 9.3.2.1 Asia Pacific: Regenerative Medicines Market - Revenue and Forecast Analysis - by Product Type
      • 9.3.2.2 Asia Pacific: Regenerative Medicines Market - Revenue and Forecast Analysis - by Cell Based Products
      • 9.3.2.3 Asia Pacific: Regenerative Medicines Market - Revenue and Forecast Analysis - by Application
    • 9.3.3 Asia Pacific: Regenerative Medicines Market - Revenue and Forecast Analysis - by Country
      • 9.3.3.1 China: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.3.3.1.1 China: Regenerative Medicines Market Breakdown, by Product Type
        • 9.3.3.1.2 China: Regenerative Medicines Market Breakdown, by Cell Based Products
        • 9.3.3.1.3 China: Regenerative Medicines Market Breakdown, by Application
      • 9.3.3.2 Japan: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.3.3.2.1 Japan: Regenerative Medicines Market Breakdown, by Product Type
        • 9.3.3.2.2 Japan: Regenerative Medicines Market Breakdown, by Cell Based Products
        • 9.3.3.2.3 Japan: Regenerative Medicines Market Breakdown, by Application
      • 9.3.3.3 India: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.3.3.3.1 India: Regenerative Medicines Market Breakdown, by Product Type
        • 9.3.3.3.2 India: Regenerative Medicines Market Breakdown, by Cell Based Products
        • 9.3.3.3.3 India: Regenerative Medicines Market Breakdown, by Application
      • 9.3.3.4 Australia: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.3.3.4.1 Australia: Regenerative Medicines Market Breakdown, by Product Type
        • 9.3.3.4.2 Australia: Regenerative Medicines Market Breakdown, by Cell Based Products
        • 9.3.3.4.3 Australia: Regenerative Medicines Market Breakdown, by Application
      • 9.3.3.5 South Korea: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.3.3.5.1 South Korea: Regenerative Medicines Market Breakdown, by Product Type
        • 9.3.3.5.2 South Korea: Regenerative Medicines Market Breakdown, by Cell Based Products
        • 9.3.3.5.3 South Korea: Regenerative Medicines Market Breakdown, by Application
      • 9.3.3.6 Rest of APAC: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.3.3.6.1 Rest of APAC: Regenerative Medicines Market Breakdown, by Product Type
        • 9.3.3.6.2 Rest of APAC: Regenerative Medicines Market Breakdown, by Cell Based Products
        • 9.3.3.6.3 Rest of APAC: Regenerative Medicines Market Breakdown, by Application
  • 9.4 Middle East and Africa
    • 9.4.1 Middle East and Africa Regenerative Medicines Market Overview
    • 9.4.2 Middle East and Africa: Regenerative Medicines Market - Revenue, 2021-2031 (US$ Million)
      • 9.4.2.1 Middle East and Africa: Regenerative Medicines Market - Revenue and Forecast Analysis - by Product Type
      • 9.4.2.2 Middle East and Africa: Regenerative Medicines Market - Revenue and Forecast Analysis - by Cell Based Products
      • 9.4.2.3 Middle East and Africa: Regenerative Medicines Market - Revenue and Forecast Analysis - by Application
    • 9.4.3 Middle East and Africa: Regenerative Medicines Market - Revenue and Forecast Analysis - by Country
      • 9.4.3.1 Saudi Arabia: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.4.3.1.1 Saudi Arabia: Regenerative Medicines Market Breakdown, by Product Type
        • 9.4.3.1.2 Saudi Arabia: Regenerative Medicines Market Breakdown, by Cell Based Products
        • 9.4.3.1.3 Saudi Arabia: Regenerative Medicines Market Breakdown, by Application
      • 9.4.3.2 United Arab Emirates: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.4.3.2.1 United Arab Emirates: Regenerative Medicines Market Breakdown, by Product Type
        • 9.4.3.2.2 United Arab Emirates: Regenerative Medicines Market Breakdown, by Cell Based Products
        • 9.4.3.2.3 United Arab Emirates: Regenerative Medicines Market Breakdown, by Application
      • 9.4.3.3 South Africa: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.4.3.3.1 South Africa: Regenerative Medicines Market Breakdown, by Product Type
        • 9.4.3.3.2 South Africa: Regenerative Medicines Market Breakdown, by Cell Based Products
        • 9.4.3.3.3 South Africa: Regenerative Medicines Market Breakdown, by Application
      • 9.4.3.4 Rest of Middle East and Africa: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.4.3.4.1 Rest of Middle East and Africa: Regenerative Medicines Market Breakdown, by Product Type
        • 9.4.3.4.2 Rest of Middle East and Africa: Regenerative Medicines Market Breakdown, by Cell Based Products
        • 9.4.3.4.3 Rest of Middle East and Africa: Regenerative Medicines Market Breakdown, by Application
  • 9.5 South and Central America
    • 9.5.1 South and Central America Regenerative Medicines Market Overview
    • 9.5.2 South and Central America: Regenerative Medicines Market - Revenue, 2021-2031 (US$ Million)
      • 9.5.2.1 South and Central America: Regenerative Medicines Market - Revenue and Forecast Analysis - by Product Type
      • 9.5.2.2 South and Central America: Regenerative Medicines Market - Revenue and Forecast Analysis - by Cell Based Products
      • 9.5.2.3 South and Central America: Regenerative Medicines Market - Revenue and Forecast Analysis - by Application
    • 9.5.3 South and Central America: Regenerative Medicines Market - Revenue and Forecast Analysis - by Country
      • 9.5.3.1 Brazil: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.5.3.1.1 Brazil: Regenerative Medicines Market Breakdown, by Product Type
        • 9.5.3.1.2 Brazil: Regenerative Medicines Market Breakdown, by Cell Based Products
        • 9.5.3.1.3 Brazil: Regenerative Medicines Market Breakdown, by Application
      • 9.5.3.2 Argentina: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.5.3.2.1 Argentina: Regenerative Medicines Market Breakdown, by Product Type
        • 9.5.3.2.2 Argentina: Regenerative Medicines Market Breakdown, by Cell Based Products
        • 9.5.3.2.3 Argentina: Regenerative Medicines Market Breakdown, by Application
      • 9.5.3.3 Rest of South and Central America: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
        • 9.5.3.3.1 Rest of South and Central America: Regenerative Medicines Market Breakdown, by Product Type
        • 9.5.3.3.2 Rest of South and Central America: Regenerative Medicines Market Breakdown, by Cell Based Products
        • 9.5.3.3.3 Rest of South and Central America: Regenerative Medicines Market Breakdown, by Application

10. Competitive Landscape

  • 10.1 Heat Map Analysis by Key Players
  • 10.2 Company Positioning & Concentration

11. Industry Landscape

  • 11.1 Overview
  • 11.2 Product Launch, Product Approvals
  • 11.3 Expansions And Other Strategic Developments

12. Company Profiles

  • 12.1 Bristol-Myers Squibb Co
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Novartis AG
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Johnson & Johnson
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Daiichi Sankyo Co Ltd
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Takeda Pharmaceutical Co Ltd
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Japan Tissue Engineering Co., Ltd.
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 Bluebird Bio Inc
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 JCR Pharmaceuticals Co. Ltd.
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 Vertex Pharmaceuticals Inc
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments
  • 12.10 Ferring Pharmaceuticals
    • 12.10.1 Key Facts
    • 12.10.2 Business Description
    • 12.10.3 Products and Services
    • 12.10.4 Financial Overview
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Developments
  • 12.11 CSL Behring LLC
    • 12.11.1 Key Facts
    • 12.11.2 Business Description
    • 12.11.3 Products and Services
    • 12.11.4 Financial Overview
    • 12.11.5 SWOT Analysis
    • 12.11.6 Key Developments
  • 12.12 BioMarin Pharmaceutical Inc.
    • 12.12.1 Key Facts
    • 12.12.2 Business Description
    • 12.12.3 Products and Services
    • 12.12.4 Financial Overview
    • 12.12.5 SWOT Analysis
    • 12.12.6 Key Developments

13. Appendix

  • 13.1 About The Insight Partners
  • 13.2 Glossary of Terms

List Of Tables

  • Table 1. Regenerative Medicines Market Segmentation
  • Table 2. Global: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 3. Global: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 4. North America: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 5. North America: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 6. North America: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 7. North America: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 8. North America: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 9. North America: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 10. United States: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 11. United States: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 12. United States: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 13. United States: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 14. United States: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 15. United States: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 16. Canada: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 17. Canada: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 18. Canada: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 19. Canada: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 20. Canada: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 21. Canada: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 22. Mexico: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 23. Mexico: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 24. Mexico: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 25. Mexico: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 26. Mexico: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 27. Mexico: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 28. Europe: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 29. Europe: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 30. Europe: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 31. Europe: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 32. Europe: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 33. Europe: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 34. Germany: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 35. Germany: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 36. Germany: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 37. Germany: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 38. Germany: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 39. Germany: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 40. United Kingdom: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 41. United Kingdom: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 42. United Kingdom: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 43. United Kingdom: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 44. United Kingdom: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 45. United Kingdom: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 46. France: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 47. France: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 48. France: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 49. France: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 50. France: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 51. France: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 52. Italy: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 53. Italy: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 54. Italy: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 55. Italy: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 56. Italy: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 57. Italy: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 58. Spain: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 59. Spain: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 60. Spain: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 61. Spain: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 62. Spain: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 63. Spain: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 64. Rest of Europe: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 65. Rest of Europe: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 66. Rest of Europe: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 67. Rest of Europe: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 68. Rest of Europe: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 69. Rest of Europe: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 70. Asia Pacific: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 71. Asia Pacific: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 72. Asia Pacific: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 73. Asia Pacific: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 74. Asia Pacific: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 75. Asia Pacific: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 76. China: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 77. China: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 78. China: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 79. China: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 80. China: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 81. China: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 82. Japan: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 83. Japan: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 84. Japan: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 85. Japan: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 86. Japan: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 87. Japan: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 88. India: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 89. India: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 90. India: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 91. India: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 92. India: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 93. India: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 94. Australia: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 95. Australia: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 96. Australia: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 97. Australia: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 98. Australia: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 99. Australia: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 100. South Korea: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 101. South Korea: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 102. South Korea: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 103. South Korea: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 104. South Korea: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 105. South Korea: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 106. Rest of APAC: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 107. Rest of APAC: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 108. Rest of APAC: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 109. Rest of APAC: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 110. Rest of APAC: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 111. Rest of APAC: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 112. Middle East and Africa: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 113. Middle East and Africa: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 114. Middle East and Africa: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 115. Middle East and Africa: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 116. Middle East and Africa: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 117. Middle East and Africa: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 118. Saudi Arabia: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 119. Saudi Arabia: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 120. Saudi Arabia: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 121. Saudi Arabia: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 122. Saudi Arabia: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 123. Saudi Arabia: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 124. United Arab Emirates: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 125. United Arab Emirates: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 126. United Arab Emirates: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 127. United Arab Emirates: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 128. United Arab Emirates: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 129. United Arab Emirates: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 130. South Africa: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 131. South Africa: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 132. South Africa: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 133. South Africa: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 134. South Africa: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 135. South Africa: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 136. Rest of Middle East and Africa: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 137. Rest of Middle East and Africa: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 138. Rest of Middle East and Africa: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 139. Rest of Middle East and Africa: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 140. Rest of Middle East and Africa: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 141. Rest of Middle East and Africa: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 142. South and Central America: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 143. South and Central America: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 144. South and Central America: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 145. South and Central America: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 146. South and Central America: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 147. South and Central America: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 148. Brazil: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 149. Brazil: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 150. Brazil: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 151. Brazil: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 152. Brazil: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 153. Brazil: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 154. Argentina: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 155. Argentina: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 156. Argentina: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 157. Argentina: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 158. Argentina: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 159. Argentina: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 160. Rest of South and Central America: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Product Type
  • Table 161. Rest of South and Central America: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Product Type
  • Table 162. Rest of South and Central America: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Cell Based Products
  • Table 163. Rest of South and Central America: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Cell Based Products
  • Table 164. Rest of South and Central America: Regenerative Medicines Market - Revenue, 2021-2024 (US$ Million) - by Application
  • Table 165. Rest of South and Central America: Regenerative Medicines Market - Revenue Forecast, 2025-2031 (US$ Million) - by Application
  • Table 166. Heat Map Analysis by Key Players
  • Table 167. Glossary of Terms, Regenerative Medicine Market

List Of Figures

  • Figure 1. Regenerative Medicines Market Segmentation, by Geography
  • Figure 2. PEST Analysis
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Regenerative Medicines Market Revenue (US$ Million), 2021-2031
  • Figure 5. Regenerative Medicines Market Revenue (US$ Million), 2021-2031
  • Figure 6. Regenerative Medicines Market Share (%) - by Product Type (2024 and 2031)
  • Figure 7. Cell Based Products: Regenerative Medicines Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Gene Therapy: Regenerative Medicines Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 9. Tissue Engineering: Regenerative Medicines Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. Regenerative Medicines Market Share (%) - by Application (2024 and 2031)
  • Figure 11. Oncology: Regenerative Medicines Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 12. Neurological Disorders: Regenerative Medicines Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 13. Wound Healing and Skin Regeneration: Regenerative Medicines Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 14. Ophthalmology: Regenerative Medicines Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Orthopedics and Musculoskeletal: Regenerative Medicines Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 16. Immunology: Regenerative Medicines Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 17. Genetic Disorders: Regenerative Medicines Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 18. Others: Regenerative Medicines Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 19. North America: Regenerative Medicines Market - Revenue, 2021-2031 (US$ Million)
  • Figure 20. North America: Regenerative Medicines Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 21. United States: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 22. Canada: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 23. Mexico: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 24. Europe: Regenerative Medicines Market - Revenue, 2021-2031 (US$ Million)
  • Figure 25. Europe: Regenerative Medicines Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 26. Germany: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 27. United Kingdom: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 28. France: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 29. Italy: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 30. Spain: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 31. Rest of Europe: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 32. Asia Pacific: Regenerative Medicines Market - Revenue, 2021-2031 (US$ Million)
  • Figure 33. Asia Pacific: Regenerative Medicines Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 34. China: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 35. Japan: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 36. India: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 37. Australia: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 38. South Korea: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 39. Rest of APAC: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 40. Middle East and Africa: Regenerative Medicines Market - Revenue, 2021-2031 (US$ Million)
  • Figure 41. Middle East and Africa: Regenerative Medicines Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 42. Saudi Arabia: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 43. United Arab Emirates: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 44. South Africa: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 45. Rest of Middle East and Africa: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 46. South and Central America: Regenerative Medicines Market - Revenue, 2021-2031 (US$ Million)
  • Figure 47. South and Central America: Regenerative Medicines Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 48. Brazil: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 49. Argentina: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 50. Rest of South and Central America: Regenerative Medicines Market - Revenue and Forecast, 2021-2031 (US$ Million)
  • Figure 51. Company Positioning & Concentration